Drug Profile
Voxelotor - Global Blood Therapeutics
Alternative Names: GBT-440; GTx-011; OxbrytaLatest Information Update: 31 Jan 2024
Price :
$50
*
At a glance
- Originator Global Blood Therapeutics
- Developer Global Blood Therapeutics; Pfizer
- Class Antianaemics; Antifibrotics; Benzaldehydes; Ethers; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Sickle haemoglobin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Sickle cell anaemia
- Discontinued Hypoxia; Idiopathic pulmonary fibrosis
Most Recent Events
- 09 Dec 2023 Efficacy and adverse events data from a phase III trial in Sickle cell anaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 04 Oct 2023 Pfizer completes a phase I drug-drug interaction trial for Sickle cell anaemia in USA (PO, Tablet) (NCT05981365)
- 14 Jul 2023 Pfizer re-initiates an expanded-access programme for Sickle cell anaemia (In infants, In Children) in USA (PO) (NCT04724421)